These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26330331)

  • 1. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
    Deeken JF; Beumer JH; Anders NM; Wanjiku T; Rusnak M; Rudek MA
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):813-9. PubMed ID: 26330331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.
    Rudek MA; Chang CY; Steadman K; Johnson MD; Desai N; Deeken JF
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):729-36. PubMed ID: 24488374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
    Pillai VC; Venkataramanan R; Parise RA; Christner SM; Gramignoli R; Strom SC; Rudek MA; Beumer JH
    Drug Metab Dispos; 2013 Oct; 41(10):1843-51. PubMed ID: 23913028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
    Beumer JH; Pillai VC; Parise RA; Christner SM; Kiesel BF; Rudek MA; Venkataramanan R
    Br J Clin Pharmacol; 2015 Nov; 80(5):1097-108. PubMed ID: 26178713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.
    Pillai VC; Parise RA; Christner SM; Rudek MA; Beumer JH; Venkataramanan R
    J Clin Pharmacol; 2014 Nov; 54(11):1272-9. PubMed ID: 24846165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
    Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
    Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
    Smith NF; Baker SD; Gonzalez FJ; Harris JW; Figg WD; Sparreboom A
    Br J Cancer; 2008 May; 98(10):1630-2. PubMed ID: 18475295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
    de Zwart L; Snoeys J; De Jong J; Sukbuntherng J; Mannaert E; Monshouwer M
    Clin Pharmacol Ther; 2016 Nov; 100(5):548-557. PubMed ID: 27367453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
    Ogasawara K; Kam J; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):369-377. PubMed ID: 34019108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
    Rakhit A; Pantze MP; Fettner S; Jones HM; Charoin JE; Riek M; Lum BL; Hamilton M
    Eur J Clin Pharmacol; 2008 Jan; 64(1):31-41. PubMed ID: 18000659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.
    Barve A; Kovacs SJ; Ke J; Crabbe R; Grosgurin P; Menetrey A; Nicolas-Métral V; Dabovic K; Dole K; Zhang J; Praestgaard J; Sunkara G; Stein D
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):25-32. PubMed ID: 27128001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
    Posada MM; Morse BL; Turner PK; Kulanthaivel P; Hall SD; Dickinson GL
    J Clin Pharmacol; 2020 Jul; 60(7):915-930. PubMed ID: 32080863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
    Samant TS; Huth F; Umehara K; Schiller H; Dhuria SV; Elmeliegy M; Miller M; Chakraborty A; Heimbach T; He H; Ji Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):575-585. PubMed ID: 32557601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
    Chen L; Boinpally R; Gad N; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
    Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
    Li A; Yeo K; Welty D; Rong H
    Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
    Boinpally R; Gad N; Gupta S; Periclou A
    Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
    Shi JG; Chen X; Emm T; Scherle PA; McGee RF; Lo Y; Landman RR; McKeever EG; Punwani NG; Williams WV; Yeleswaram S
    J Clin Pharmacol; 2012 Jun; 52(6):809-18. PubMed ID: 21602517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
    Moltó J; Rajoli R; Back D; Valle M; Miranda C; Owen A; Clotet B; Siccardi M
    J Antimicrob Chemother; 2017 Mar; 72(3):805-811. PubMed ID: 27999009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
    Courlet P; Guidi M; Alves Saldanha S; Cavassini M; Stoeckle M; Buclin T; Marzolini C; Decosterd LA; Csajka C
    Eur J Clin Pharmacol; 2021 Jul; 77(7):979-987. PubMed ID: 33452585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.